BioSpace News Archive

AIM ImmunoTech Inc. announced that oncology experts from Roswell Park Comprehensive Cancer Center will present findings from two ongoing clinical studies involving an AIM ImmunoTech Inc. drug candidate, Ampligen® at the American Association for Cancer Research Annual Meeting 2022, being held April 8-13, 2022, in New Orleans, Louisiana.

Cyclacel Pharmaceuticals, Inc. today announced that management will be presenting at the virtual 32nd Annual Oppenheimer Healthcare Conference and participating in the Targeted Oncology Panel as part of the Conference.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company’s senior management team will participate in a fireside chat at the Barclays Global Healthcare Conference.

Lyra Therapeutics, Inc. today reported financial results for the quarter ended December 31, 2021, and highlighted recent accomplishments and upcoming milestones.

Marengo Therapeutics, Inc., a company pioneering novel therapeutics that selectively activate T cells via the T cell receptor Vβ chain to combat cancer, announced that it will participate in the following investor, scientific, and industry conferences.

Deciphera Pharmaceuticals, Inc. announced that Tucker Kelly, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022 at 4:20 PM ET in Miami.

Ocugen, Inc. today announces that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, Inc., will be presenting at the 34th Annual Roth Conference.

Amsterdam, the Netherlands – Royal Philips, a global leader in health technology, has announced new research evaluating mobile cardiac outpatient telemetry as a first-line diagnostic ambulatory monitoring solution with post-cryptogenic stroke patients.

Antengene Corporation Limited announced that the Therapeutic Goods Administration of the Australian Government Department of Health has registered XPOVIO® for two indications.

Seneca Therapeutics, Inc. announced the publication of an abstract “Oncolytic Seneca Valley Virus overcomes checkpoint inhibitor resistance and demonstrates a systemic anti-tumor immune response in a syngeneic pancreatic cancer murine model” at the upcoming American Association for Cancer Research meeting in New Orleans, LA.